Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

England: HTA Body’s Income Hit By COVID-19

Executive Summary

England’s health technology assessment body NICE did not recover costs for technology appraisals through fees thanks to the COVID-19 pandemic.

You may also be interested in...



Tumor-Agnostic First In England As NICE Reverses Vitrakvi Rejection

Bayer’s “game-changing” histology-independent treatment is to be made available via the Cancer Drugs Fund.

UK’s NICE Under Fire For New HTA Fees

Fees for appraisals that the health technology assessment body, NICE, will introduce in April could adversely impact companies with medicines for smaller indications, despite a bigger fee reduction for some manufacturers.

England Unveils £680m Innovative Medicines Fund

England’s Innovative Medicines Fund is aimed at providing earlier access to promising new treatments, including gene therapies, when further data is needed for routine commissioning.

Topics

UsernamePublicRestriction

Register

PS144647

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel